Optic neuropathy and recurrence of papilledema in patients with craniosynostosis may be a clinically useful biomarker by PHOMS.
People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback